Hypha Labs (FUNI) 10-Q 12 Feb 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Dec. 31, 2020	Feb. 12, 2021
Cover [Abstract]
Entity Registrant Name	Digipath, Inc.
Entity Central Index Key	0001502966
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		64,065,390
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Current assets:
Cash	$ 79,070	$ 82,749
Accounts receivable, net	130,259	242,145
Other current assets	45,222	53,673
Deposits	18,675	18,675
Total current assets	273,226	397,242
Right-of-use asset	483,200	505,706
Fixed assets, net	802,140	885,405
Total Assets	1,558,566	1,788,353
Current liabilities:
Accounts payable	460,088	387,946
Accrued expenses	159,887	163,152
Short term advances	50,112	50,112
Current portion of operating lease liabilities	86,889	84,731
Current portion of finance lease liabilities	34,053	32,532
Current maturities of notes payable	55,102	54,317
Total current liabilities	846,131	772,790
Non-current liabilities:
Operating lease liabilities	401,170	423,752
Finance lease liabilities	11,912	20,379
Notes payable	404,833	418,907
Convertible notes payable, net of discounts of $-0- and $8,322 at December 31, 2020 and September 30, 2020, respectively	1,200,000	1,241,678
Total non-current liabilities	2,017,915	2,104,716
Total Liabilities	2,864,046	2,877,506
Stockholders' Equity (Deficit):
Series A convertible preferred stock, $0.001 par value, 10,000,000 shares authorized; 1,325,942 shares issued and outstanding	1,326	1,326
Common stock, $0.001 par value, 250,000,000 shares authorized; 64,065,390 and 58,270,567 shares issued and outstanding at December 31, 2020 and September 30, 2020, respectively	64,065	58,271
Additional paid-in capital	16,284,916	16,116,400
Accumulated (deficit)	(17,655,787)	(17,265,150)
Total Stockholders' Equity (Deficit)	(1,305,480)	(1,089,153)
Total Liabilities and Stockholders' Equity (Deficit)	$ 1,558,566	$ 1,788,353

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Convertible notes payable discounts non-current	$ 0	$ 8,322	$ 8,322
Series A convertible preferred stock, par value	$ 0.001	$ 0.001
Series A convertible preferred stock, shares authorized	10,000,000	10,000,000
Series A convertible preferred stock, shares issued	1,325,942	1,325,942
Series A convertible preferred stock, shares outstanding	1,325,942	1,325,942
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	64,065,390	58,270,567
Common stock, shares outstanding	64,065,390	58,270,567

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 500,385	$ 808,930
Cost of sales	420,885	405,481
Gross profit	79,500	403,449
Operating expenses:
General and administrative	225,050	388,432
Professional fees	114,544	183,633
Bad debts expense	88,170	43,250
Total operating expenses	427,764	615,315
Operating loss	(348,264)	(211,866)
Other income (expense):
Other income		21,000
Interest expense	(42,373)	(29,561)
Total other income (expense)	(42,373)	(8,561)
Net loss	$ (390,637)	$ (220,427)
Weighted average number of common shares outstanding - basic and fully diluted	58,423,853	48,372,600
Net loss per share - basic and fully diluted	$ (0.01)	$ 0

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated (Deficit) [Member]	Total
Balance at Sep. 30, 2019	$ 1,326	$ 48,361	$ 15,331,839	$ (14,955,660)	$ 425,866
Balance, shares at Sep. 30, 2019	1,325,942	48,361,433
Common stock issued for services		$ 172	24,578		24,750
Common stock issued for services, shares		171,233
Common stock options issued for services			17,677		17,677
Net loss				(220,427)	(220,427)
Balance at Dec. 31, 2019	$ 1,326	$ 48,533	15,374,094	(15,176,087)	247,866
Balance, shares at Dec. 31, 2019	1,325,942	48,532,666
Balance at Sep. 30, 2020	$ 1,326	$ 58,271	16,116,400	(17,265,150)	(1,089,153)
Balance, shares at Sep. 30, 2020	1,325,942	58,270,567
Common stock sold for cash		$ 900	19,350		20,250
Common stock sold for cash, shares		900,000
Common stock issued for debt conversions		$ 3,666	106,334		110,000
Common stock issued for debt conversions, shares		3,666,668
Common stock issued for services		$ 1,228	25,772		27,000
Common stock issued for services, shares		1,228,155
Common stock options issued for services			17,060		17,060
Net loss				(390,637)	(390,637)
Balance at Dec. 31, 2020	$ 1,326	$ 64,065	$ 16,284,916	$ (17,655,787)	$ (1,305,480)
Balance, shares at Dec. 31, 2020	1,325,942	64,065,390

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (390,637)	$ (220,427)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance for doubtful accounts	88,170	43,250
Depreciation and amortization expense	83,265	70,874
Stock issued for services	27,000	24,750
Options and warrants granted for services	17,060	17,677
Amortization of debt discounts	8,322	8,321
Decrease (increase) in assets:
Accounts receivable	23,716	(146,062)
Other current assets	8,451	19,663
Inventory		(37,900)
Deposits		26,057
Right-of-use assets	22,506	47,376
Increase (decrease) in liabilities:
Accounts payable	72,142	77,842
Accrued expenses	(3,265)	(48,947)
Lease liabilities	(20,424)	(46,398)
Net cash used in operating activities	(63,694)	(163,924)
Cash flows from investing activities
Purchase of fixed assets		(90,315)
Net cash used in investing activities		(90,315)
Cash flows from financing activities
Proceeds from short term advances		25,000
Principal payments on finance lease	(6,946)	(25,843)
Principal payments on note payable, equipment financing	(13,289)
Proceeds from convertible notes	60,000
Proceeds from sale of common stock	20,250
Net cash provided by (used in) financing activities	60,015	(843)
Net decrease in cash	(3,679)	(255,082)
Cash - beginning	82,749	323,739
Cash - ending	79,070	68,657
Supplemental disclosures:
Interest paid	14,179	7,125
Income taxes paid
Non-cash investing and financing activities:
Fixed assets acquired with capitalized finance lease		99,193
Fixed assets acquired with note payable, equipment financing		291,931
Value of shares issued for conversion of debt	$ 110,000

Organization, Basis of Presenta

Organization, Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Organization, Basis of Presentation and Significant Accounting Policies	Note 1 – Organization, Basis of Presentation and Significant Accounting Policies Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and hopes to open labs in other states and countries that have legalized the sale of cannabis, beginning with California or Arizona. Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2020: Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of lab testing services through our subsidiary Digipath Labs, Inc. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	3 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying condensed consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of $17,655,787, negative working capital of $572,905, and as of December 31, 2020, the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new customers to increase revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Common Stock Sold for Cash On December 30, 2020, the Company sold 900,000 shares of its common stock to its Chairman of the Board in exchange for proceeds of $20,250. Common Stock Issued for Services On December 25, 2020, the Company issued 728,155 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2020 and September 30, 2020, respectively: Fair Value Measurements at December 31, 2020 Level 1 Level 2 Level 3 Assets Cash $ 79,070 $ - $ - Total assets 79,070 - - Liabilities Short term advances - 50,112 - Lease liabilities - - 534,024 Notes payable - 459,935 - Convertible notes payable - - 1,200,000 Total liabilities - 510,047 1,734,024 $ 79,070 $ (510,047 ) $ (1,734,024 ) Fair Value Measurements at September 30, 2020 Level 1 Level 2 Level 3 Assets Cash $ 82,749 $ - $ - Total assets 82,749 - - Liabilities Short term advances - 50,112 - Lease liabilities - - 561,394 Notes payable - 473,224 - Convertible notes payable, net of discounts of $8,322 - - 1,241,678 Total liabilities - 523,336 1,803,072 $ 82,749 $ (523,336 ) $ (1,803,072 ) The fair value of our intellectual properties are deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. Level 3 liabilities consist of lease liabilities and a total of $1,200,000 of convertible debentures and $1,250,000 of convertible debentures, net of discounts of $8,322, as of December 31, 2020 and September 30, 2020, respectively. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended December 31, 2020 or the year ended September 30, 2020.

Accounts Receivable

Accounts Receivable	3 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Accounts Receivable	Note 5 – Accounts Receivable Accounts receivable was $130,259 and $242,145 at December 31, 2020 and September 30, 2020, respectively, net of allowance for uncollectible accounts of $216,302 and $128,944 at December 31, 2020 and September 30, 2020, respectively.

Other Current Assets

Other Current Assets	3 Months Ended
	Dec. 31, 2020
Other Current Assets
Other Current Assets	Note 6 – Other Current Assets Other current assets consist of the following: December 31, September 30, 2020 2020 Prepaid expenses $ 39,901 $ 48,151 Other receivable 5,321 5,522 Total other current assets $ 45,222 $ 53,673

Fixed Assets

Fixed Assets	3 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 7 – Fixed Assets Fixed assets consist of the following at December 31, 2020 and September 30, 2020: December 31, September 30, 2020 2020 Software $ 124,697 $ 124,697 Office equipment 74,777 74,777 Furniture and fixtures 29,879 29,879 Lab equipment 1,398,716 1,398,716 Leasehold improvements 494,117 494,117 Lab equipment held under capital leases 99,193 99,193 2,221,379 2,221,379 Less: accumulated depreciation (1,419,239 ) (1,335,974 ) Total $ 802,140 $ 885,405 Depreciation and amortization expense totaled $83,265 and $70,874 for the three months ended December 31, 2020 and 2019, respectively.

Leases

Leases	3 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	Note 8 – Leases The Company leases its operating and office facility under a non-cancelable real property lease agreement that expires on August 31, 2025. The Company also has a financing lease for lab equipment subject to the recently adopted ASU 2016-02. In the locations in which it is economically feasible to continue to operate, management expects to enter into a new lease upon expiration. The real property lease contains provisions requiring payment of property taxes, utilities, insurance, maintenance and other occupancy costs applicable to the leased premise. As the Company’s leases do not provide implicit discount rates, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The components of lease expense were as follows: For the Three Months Ended December 31, 2020 Operating lease cost $ 29,718 Finance lease cost: Amortization of assets 6,946 Interest on lease liabilities 2,330 Total lease cost $ 38,994 Supplemental balance sheet information related to leases was as follows: December 31, 2020 Operating leases: Operating lease assets $ 483,200 Current portion of operating lease liabilities $ 86,889 Noncurrent operating lease liabilities 401,170 Total operating lease liabilities $ 488,059 Finance lease: Equipment, at cost $ 99,193 Accumulated amortization (24,798 ) Equipment, net $ 74,395 Current portion of finance lease liability $ 34,053 Noncurrent finance lease liability 11,912 Total finance lease liability $ 45,965 Weighted average remaining lease term: Operating leases 4.67 years Finance leases 1.30 years Weighted average discount rate: Operating leases 5.75 % Finance lease 18.41 % Supplemental cash flow and other information related to leases was as follows: For the Three Months Ended December 31, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used for operating leases $ 20,424 Financing cash flows used for finance leases $ 6,946 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ 528,616 Total finance lease liabilities $ 99,193 The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of December 31, 2020: Fiscal Year Ending Minimum Lease September 30, Commitments 2021* $ 84,147 2022 115,550 2023 119,468 2024 123,543 2025 116,891 $ 559,599 * Liability pertains to the remaining nine month period from January 1, 2021 through September 30, 2021. Future minimum annual lease payments required under the finance lease and the present value of the net minimum lease payments are as follows at December 31, 2020: Finance Leases 2021* $ 30,921 2022 21,644 Total minimum lease payments 52,565 Less interest 6,600 Present value of lease liabilities 45,965 Less current portion 34,053 Long-term lease liabilities $ 11,912 * Liability pertains to the remaining nine month period from January 1, 2021 through September 30, 2021.

Short Term Advances

Short Term Advances	3 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Short Term Advances	Note 9 – Short Term Advances Short term advances consist of the following at December 31, 2020 and September 30, 2019, respectively: December 31, September 30, 2020 2020 On July 20, 2020, we received $30,112 as a short-term loan from one of our convertible noteholders. The loan bears interest at the rate of 8.0% per annum. $ 30,112 $ 30,112 On January 21, 2020, we received $20,000 as a short-term loan from one of our convertible noteholders. No interest expense was recognized. 20,000 20,000 On December 26, 2019, we received $25,000 as a short-term loan from one of our convertible noteholders. The advance was subsequently repaid on February 6, 2020. No interest expense was recognized. - - Total short term advances $ 50,112 $ 50,112 The Company recorded interest expense pursuant to the stated interest rates on the short term loans in the amount of $1,023 for the three months ended December 31, 2020.

Notes Payable

Notes Payable	3 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	Note 10 –Notes Payable Notes payable consists of the following at December 31, 2020 and September 30, 2019, respectively: December 31, September 30, 2020 2020 On June 22, 2020, the Company, borrowed $40,114 from Cross River Bank, pursuant to a Promissory Note issued by the Company to Cross River Bank (the “Company PPP Note”). The loan was made pursuant to the Payroll Protection Program established as part of the Coronavirus Aid, Relief, and Economic Security Act (the “Payroll Protection Program”). The Company PPP Note carried interest at 1.00% per annum, payable monthly beginning December 22, 2020, and was due on June 22, 2025. The Digipath, Inc. Subsequent to the end of the quarter ended December 31, 2021, PPP Note and interest was forgiven by the Small Business Administration (“SBA”) on January 12, 2021. $ 40,114 $ 40,114 On May 13, 2020, the Company, through its wholly-owned subsidiary Digipath Labs, Inc. (“Labs”), borrowed $179,920 from WebBank Corp, pursuant to a Promissory Note issued by Labs to WebBank Corp (the “Labs PPP Note”). The loan was made pursuant to the Payroll Protection Program. The Labs PPP Note bears interest at 1.00% per annum, payable monthly beginning December 13, 2020, and is due on May 13, 2022. The Labs PPP Note may be repaid at any time without penalty. 179,920 179,920 On December 26, 2019, the Company financed the purchase of $377,124 of lab equipment, in part, with the proceeds of a bank loan in the amount of $291,931. The loan bears interest at the rate of 5.75% per annum and requires monthly payments of $5,622 over the five-year term of the loan ending on December 26, 2024. The Company’s obligations under this loan are secured by a lien on the purchased equipment. 239,901 253,190 Total notes payable 459,935 473,224 Less: current maturities (55,102 ) (54,317 ) Notes payable $ 404,833 $ 418,907 The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $4,131 and $3,819 during the three months ended December 31, 2020 and 2019, respectively.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 11 – Convertible Notes Payable Convertible notes payable consists of the following at December 31, 2020 and September 30, 2020, respectively: December 31, September 30, 2020 2020 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $50,000. The Note matures on August 11, 2022, bears interest at a rate of 9% per annum, and was convertible into shares of the Company’s common stock at a conversion price of $0.15 per share. On December 28, 2020, the conversion price was amended to $0.03 per share in exchange for an additional $10,000 of proceeds and the promissory note was increased to $60,000. The Company’s obligations under the Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc., pursuant to a Security Agreement between the Company, Digipath Labs, Inc. and the investor. On December 29, 2020, the note holder converted $10,000 of principal into 333,334 shares of common stock at a conversion price of $0.03 per share. $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $150,000. The Note matures on August 11, 2022, bears interest at a rate of 9% per annum, and was convertible into shares of the Company’s common stock at a conversion price of $0.15 per share. On December 28, 2020, the conversion price was amended to $0.03 per share in exchange for an additional $50,000 of proceeds and the promissory note was increased to $200,000. The Company’s obligations under the Note are secured by subordinated lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc., pursuant to a Security Agreement between the Company, Digipath Labs, Inc. and the investor. On December 29, 2020, the note holder converted $50,000 of principal into 1,666,667 shares of common stock at a conversion price of $0.03 per share. 150,000 150,000 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $350,000. The Note matures on August 10, 2022, bears interest at a rate of 9% per annum, and was convertible into shares of the Company’s common stock at a conversion price of $0.15 per share. On December 28, 2020, the conversion price was amended to $0.03 per share in exchange for an additional $50,000 of proceeds that were received on January 4, 2021, and the promissory note was increased to $400,000. The Company’s obligations under the Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc., pursuant to a Security Agreement between the Company, Digipath Labs, Inc. and the investor. On December 29, 2020, the note holder converted $50,000 of principal into 1,666,667 shares of common stock at a conversion price of $0.03 per share. 300,000 350,000 On September 23, 2019, the Company received proceeds of $200,000 on a senior secured convertible note that carries an 8% interest rate, which matures on August 10, 2022, as amended. The principal and interest were convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.11 per share. On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. 200,000 200,000 On November 8, 2018, the Company received proceeds of $350,000 on a senior secured convertible note that carries an 8% interest rate, which matures on August 10, 2022, as amended. The principal and interest were convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.14 per share. On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. A total of $4,066 of interest was repaid during the year ended September 30, 2019. 350,000 350,000 On November 5, 2018, the Company received proceeds of $150,000 on a senior secured convertible note that carries an 8% interest rate, which matures on August 10, 2022, as amended. The principal and interest were convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.14 per share. On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. 150,000 150,000 Total convertible notes payable 1,200,000 1,250,000 Less: unamortized debt discounts - (8,322 ) 1,200,000 1,241,678 Less: current maturities - - Convertible notes payable $ 1,200,000 $ 1,241,678 In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $70,964. The discount is amortized on a straight-line basis from the dates of issuance until the earlier of the stated redemption date of the debts, as noted above or the actual settlement date. The Company recorded debt amortization expense on the aforementioned debt discount in the amount of $-0- and $8,322 during the three months ended December 31, 2020 and 2019, respectively. All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99% of the Company’s issued and outstanding shares. The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $26,567 and $14,115 for the three months ended December 31, 2020 and 2019, respectively. The Company recognized interest expense for the three months ended December 31, 2020 and 2019, respectively, as follows: December 31, December 31, 2020 2019 Interest on short term loans $ 1,023 $ - Interest on capital leases 2,330 3,306 Interest on notes payable 4,131 3,819 Amortization of beneficial conversion features 8,322 8,321 Interest on convertible notes 26,567 14,115 Total interest expense $ 42,373 $ 29,561

Changes in Stockholders' Equity

Changes in Stockholders' Equity	3 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Changes in Stockholders' Equity	Note 12 - Changes in Stockholders’ Equity Convertible Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, of which 6,000,000 have been designated as Series A Convertible Preferred Stock (“Series A Preferred”), with the remaining 4,000,000 shares available for designation from time to time by the Board as set forth below. As of December 31, 2020, there were 1,325,942 shares of Series A Preferred issued and outstanding. The Board of Directors is authorized to determine any number of series into which the undesignated shares of preferred stock may be divided and to determine the rights, preferences, privileges and restrictions granted to any series of the preferred stock. Each share of Series A Preferred is currently convertible into five shares of common stock. The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,325,942 shares of Series A Preferred outstanding at December 31, 2020 are convertible into 6,629,710 shares of the common stock of the Company. No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Common Stock Common stock consists of $0.001 par value, 250,000,000 shares authorized, of which 64,065,390 shares were issued and outstanding as of February 12, 2021. Common Stock Sales On December 30, 2020, the Company sold 900,000 shares of its common stock to its Chairman of the Board in exchange for proceeds of $20,250. Debt Conversions On December 29, 2020, the three holders of the Company’s 9% Secured Convertible Notes converted debt in the aggregate original principal amount of $110,000 into an aggregate of 3,666,668 shares at a conversion price of $0.03 per share. Common Stock Issued for Services On December 28, 2020, the Company issued 500,000 shares of common stock to a consultant for services rendered pursuant to his consulting agreement. The aggregate fair value of the common stock was $12,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On December 25, 2020, the Company issued 728,155 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. Amortization of Stock-Based Compensation A total of $17,060 of stock-based compensation expense was recognized from the amortization of options and warrants over their vesting period during the three months ended December 31, 2020.

Common Stock Options

Common Stock Options	3 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Common Stock Options	Note 13 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012 and previously amended on May 20, 2014. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 shares of common stock pursuant to the grant of options or other awards, including stock grants, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2012 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. A total of 2,820,000 options were outstanding as of December 31, 2020. During the three months ended December 31, 2020, options to purchase an aggregate total of 750,000 shares of common stock at a weighted average exercise price of $0.10 per share expired.

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Common Stock Warrants	Note 14 – Common Stock Warrants Warrants to purchase a total of 3,877,024 shares of common stock were outstanding as of December 31, 2020. During the three months ended December 31, 2020, warrants to purchase an aggregate total of 397,245 shares of common stock at a weighted average exercise price of $0.26 per share expired.

Other Income (Expense)

Other Income (Expense)	3 Months Ended
	Dec. 31, 2020
Other Income and Expenses [Abstract]
Other Income (Expense)	Note 15 – Other Income (Expense) Other income (expense) for the three months ended December 31, 2020 and 2019 consisted of the following: December 31, 2020 2019 Rental income on subleases $ - $ 21,000 Interest expense (42,373 ) (29,561 ) $ (42,373 ) $ (8,561 )

Income Tax

Income Tax	3 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax	Note 16 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the three months ended December 31, 2020 and the year ended September 30, 2020, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2020, the Company had approximately $13,056,000 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2020 and September 30, 2020, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events Debt Forgiveness On January 12, 2021, the Company PPP Note and interest in the principal amount of $40,114 was forgiven under the Payroll Protection Program.

Organization, Basis of Presen_2

Organization, Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Organization	Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and hopes to open labs in other states and countries that have legalized the sale of cannabis, beginning with California or Arizona.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2020: Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short-term nature of the instruments.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of lab testing services through our subsidiary Digipath Labs, Inc. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements	Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Organization, Basis of Presen_3

Organization, Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2020: Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2020 and September 30, 2020, respectively: Fair Value Measurements at December 31, 2020 Level 1 Level 2 Level 3 Assets Cash $ 79,070 $ - $ - Total assets 79,070 - - Liabilities Short term advances - 50,112 - Lease liabilities - - 534,024 Notes payable - 459,935 - Convertible notes payable - - 1,200,000 Total liabilities - 510,047 1,734,024 $ 79,070 $ (510,047 ) $ (1,734,024 ) Fair Value Measurements at September 30, 2020 Level 1 Level 2 Level 3 Assets Cash $ 82,749 $ - $ - Total assets 82,749 - - Liabilities Short term advances - 50,112 - Lease liabilities - - 561,394 Notes payable - 473,224 - Convertible notes payable, net of discounts of $8,322 - - 1,241,678 Total liabilities - 523,336 1,803,072 $ 82,749 $ (523,336 ) $ (1,803,072 )

Other Current Assets (Tables)

Other Current Assets (Tables)	3 Months Ended
	Dec. 31, 2020
Other Current Assets
Schedule of Other Current Assets	Other current assets consist of the following: December 31, September 30, 2020 2020 Prepaid expenses $ 39,901 $ 48,151 Other receivable 5,321 5,522 Total other current assets $ 45,222 $ 53,673

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at December 31, 2020 and September 30, 2020: December 31, September 30, 2020 2020 Software $ 124,697 $ 124,697 Office equipment 74,777 74,777 Furniture and fixtures 29,879 29,879 Lab equipment 1,398,716 1,398,716 Leasehold improvements 494,117 494,117 Lab equipment held under capital leases 99,193 99,193 2,221,379 2,221,379 Less: accumulated depreciation (1,419,239 ) (1,335,974 ) Total $ 802,140 $ 885,405

Leases (Tables)

Leases (Tables)	3 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense were as follows: For the Three Months Ended December 31, 2020 Operating lease cost $ 29,718 Finance lease cost: Amortization of assets 6,946 Interest on lease liabilities 2,330 Total lease cost $ 38,994
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows: December 31, 2020 Operating leases: Operating lease assets $ 483,200 Current portion of operating lease liabilities $ 86,889 Noncurrent operating lease liabilities 401,170 Total operating lease liabilities $ 488,059 Finance lease: Equipment, at cost $ 99,193 Accumulated amortization (24,798 ) Equipment, net $ 74,395 Current portion of finance lease liability $ 34,053 Noncurrent finance lease liability 11,912 Total finance lease liability $ 45,965 Weighted average remaining lease term: Operating leases 4.67 years Finance leases 1.30 years Weighted average discount rate: Operating leases 5.75 % Finance lease 18.41 %
Schedule of Supplemental Cash Flow and Other Information	Supplemental cash flow and other information related to leases was as follows: For the Three Months Ended December 31, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used for operating leases $ 20,424 Financing cash flows used for finance leases $ 6,946 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ 528,616 Total finance lease liabilities $ 99,193
Schedule of Future Minimum Annual Lease Commitments Under Operating Leases	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of December 31, 2020: Fiscal Year Ending Minimum Lease September 30, Commitments 2021* $ 84,147 2022 115,550 2023 119,468 2024 123,543 2025 116,891 $ 559,599 * Liability pertains to the remaining nine month period from January 1, 2021 through September 30, 2021.
Schedule of Future Minimum Annual Lease Payments Under Finance Lease	Future minimum annual lease payments required under the finance lease and the present value of the net minimum lease payments are as follows at December 31, 2020: Finance Leases 2021* $ 30,921 2022 21,644 Total minimum lease payments 52,565 Less interest 6,600 Present value of lease liabilities 45,965 Less current portion 34,053 Long-term lease liabilities $ 11,912 * Liability pertains to the remaining nine month period from January 1, 2021 through September 30, 2021.

Short Term Advances (Tables)

Short Term Advances (Tables)	3 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Short Term Advances	Short term advances consist of the following at December 31, 2020 and September 30, 2019, respectively: December 31, September 30, 2020 2020 On July 20, 2020, we received $30,112 as a short-term loan from one of our convertible noteholders. The loan bears interest at the rate of 8.0% per annum. $ 30,112 $ 30,112 On January 21, 2020, we received $20,000 as a short-term loan from one of our convertible noteholders. No interest expense was recognized. 20,000 20,000 On December 26, 2019, we received $25,000 as a short-term loan from one of our convertible noteholders. The advance was subsequently repaid on February 6, 2020. No interest expense was recognized. - - Total short term advances $ 50,112 $ 50,112

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at December 31, 2020 and September 30, 2019, respectively: December 31, September 30, 2020 2020 On June 22, 2020, the Company, borrowed $40,114 from Cross River Bank, pursuant to a Promissory Note issued by the Company to Cross River Bank (the “Company PPP Note”). The loan was made pursuant to the Payroll Protection Program established as part of the Coronavirus Aid, Relief, and Economic Security Act (the “Payroll Protection Program”). The Company PPP Note carried interest at 1.00% per annum, payable monthly beginning December 22, 2020, and was due on June 22, 2025. The Digipath, Inc. Subsequent to the end of the quarter ended December 31, 2021, PPP Note and interest was forgiven by the Small Business Administration (“SBA”) on January 12, 2021. $ 40,114 $ 40,114 On May 13, 2020, the Company, through its wholly-owned subsidiary Digipath Labs, Inc. (“Labs”), borrowed $179,920 from WebBank Corp, pursuant to a Promissory Note issued by Labs to WebBank Corp (the “Labs PPP Note”). The loan was made pursuant to the Payroll Protection Program. The Labs PPP Note bears interest at 1.00% per annum, payable monthly beginning December 13, 2020, and is due on May 13, 2022. The Labs PPP Note may be repaid at any time without penalty. 179,920 179,920 On December 26, 2019, the Company financed the purchase of $377,124 of lab equipment, in part, with the proceeds of a bank loan in the amount of $291,931. The loan bears interest at the rate of 5.75% per annum and requires monthly payments of $5,622 over the five-year term of the loan ending on December 26, 2024. The Company’s obligations under this loan are secured by a lien on the purchased equipment. 239,901 253,190 Total notes payable 459,935 473,224 Less: current maturities (55,102 ) (54,317 ) Notes payable $ 404,833 $ 418,907

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consists of the following at December 31, 2020 and September 30, 2020, respectively: December 31, September 30, 2020 2020 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $50,000. The Note matures on August 11, 2022, bears interest at a rate of 9% per annum, and was convertible into shares of the Company’s common stock at a conversion price of $0.15 per share. On December 28, 2020, the conversion price was amended to $0.03 per share in exchange for an additional $10,000 of proceeds and the promissory note was increased to $60,000. The Company’s obligations under the Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc., pursuant to a Security Agreement between the Company, Digipath Labs, Inc. and the investor. On December 29, 2020, the note holder converted $10,000 of principal into 333,334 shares of common stock at a conversion price of $0.03 per share. $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $150,000. The Note matures on August 11, 2022, bears interest at a rate of 9% per annum, and was convertible into shares of the Company’s common stock at a conversion price of $0.15 per share. On December 28, 2020, the conversion price was amended to $0.03 per share in exchange for an additional $50,000 of proceeds and the promissory note was increased to $200,000. The Company’s obligations under the Note are secured by subordinated lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc., pursuant to a Security Agreement between the Company, Digipath Labs, Inc. and the investor. On December 29, 2020, the note holder converted $50,000 of principal into 1,666,667 shares of common stock at a conversion price of $0.03 per share. 150,000 150,000 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $350,000. The Note matures on August 10, 2022, bears interest at a rate of 9% per annum, and was convertible into shares of the Company’s common stock at a conversion price of $0.15 per share. On December 28, 2020, the conversion price was amended to $0.03 per share in exchange for an additional $50,000 of proceeds that were received on January 4, 2021, and the promissory note was increased to $400,000. The Company’s obligations under the Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc., pursuant to a Security Agreement between the Company, Digipath Labs, Inc. and the investor. On December 29, 2020, the note holder converted $50,000 of principal into 1,666,667 shares of common stock at a conversion price of $0.03 per share. 300,000 350,000 On September 23, 2019, the Company received proceeds of $200,000 on a senior secured convertible note that carries an 8% interest rate, which matures on August 10, 2022, as amended. The principal and interest were convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.11 per share. On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. 200,000 200,000 On November 8, 2018, the Company received proceeds of $350,000 on a senior secured convertible note that carries an 8% interest rate, which matures on August 10, 2022, as amended. The principal and interest were convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.14 per share. On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. A total of $4,066 of interest was repaid during the year ended September 30, 2019. 350,000 350,000 On November 5, 2018, the Company received proceeds of $150,000 on a senior secured convertible note that carries an 8% interest rate, which matures on August 10, 2022, as amended. The principal and interest were convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.14 per share. On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. 150,000 150,000 Total convertible notes payable 1,200,000 1,250,000 Less: unamortized debt discounts - (8,322 ) 1,200,000 1,241,678 Less: current maturities - - Convertible notes payable $ 1,200,000 $ 1,241,678
Schedule of Interest Expense	The Company recognized interest expense for the three months ended December 31, 2020 and 2019, respectively, as follows: December 31, December 31, 2020 2019 Interest on short term loans $ 1,023 $ - Interest on capital leases 2,330 3,306 Interest on notes payable 4,131 3,819 Amortization of beneficial conversion features 8,322 8,321 Interest on convertible notes 26,567 14,115 Total interest expense $ 42,373 $ 29,561

Other Income (Expense) (Tables)

Other Income (Expense) (Tables)	3 Months Ended
	Dec. 31, 2020
Other Income and Expenses [Abstract]
Schedule of Other Income (Expense)	Other income (expense) for the three months ended December 31, 2020 and 2019 consisted of the following: December 31, 2020 2019 Rental income on subleases $ - $ 21,000 Interest expense (42,373 ) (29,561 ) $ (42,373 ) $ (8,561 )

Organization, Basis of Presen_4

Organization, Basis of Presentation and Significant Accounting Policies (Details Narrative)	3 Months Ended
	Dec. 31, 2020Segment
Accounting Policies [Abstract]
Entity incorporation, date of incorporation	Oct. 5, 2010
Entity incorporation, state or country code	NV
Number of reportable segment	1

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	3 Months Ended
	Dec. 31, 2020
Entities Under Common Control and Ownership One [Member]
Name of Entity	Digipath, Inc.	[1],[2]
Jurisdiction of Incorporation	Nevada
Relationship	Parent
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Digipath Labs, Inc.	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	TNM News, Inc.	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs S.A.S.	[1],[3]
Jurisdiction of Incorporation	Colombia
Relationship	Subsidiary
Entities Under Common Control and Ownership Five [Member]
Name of Entity	VSSL Enterprises, Ltd	[1],[4]
Jurisdiction of Incorporation	Canada
Relationship	Subsidiary
[1]	All entities are in the form of a corporation.
[2]	Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.
[3]	Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.
[4]	Acquired on March 11, 2020.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (17,655,787)	$ (17,265,150)
Working capital	$ (572,905)

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 30, 2020	Dec. 25, 2020	Dec. 31, 2020	Dec. 31, 2019
Common stock shares issued for services, value			$ 27,000	$ 24,750
Chief Financial Officer [Member]
Common stock issued for services, shares		728,155
Common stock shares issued for services, value		$ 15,000
Chief Financial Officer [Member] | Employment Agreement [Member]
Common stock issued for services, shares		728,155
Common stock shares issued for services, value		$ 15,000
Common Stock [Member]
Common stock issued for services, shares			1,228,155	171,233
Common stock shares issued for services, value			$ 1,228	$ 172
Common Stock [Member] | Chairman [Member]
Common stock sold for cash, shares	900,000
Proceeds from sale of common stock	$ 20,250

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details Narrative) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Convertible debentures	$ 1,200,000	$ 1,250,000
Convertible notes discounts		$ 8,322

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Level 1 [Member]
Cash	$ 79,070	$ 82,749
Total assets	79,070	82,749
Short term advances
Lease liabilities
Note payable
Convertible notes payable, net of discounts
Total liabilities
Total	79,070	82,749
Level 2 [Member]
Cash
Total assets
Short term advances	50,112	50,112
Lease liabilities
Note payable	459,935	473,224
Convertible notes payable, net of discounts
Total liabilities	510,047	523,336
Total	(510,047)	(523,336)
Level 3 [Member]
Cash
Total assets
Short term advances
Lease liabilities	534,024	561,394
Note payable
Convertible notes payable, net of discounts	1,200,000	1,241,678
Total liabilities	1,734,024	1,803,072
Total	$ (1,734,024)	$ (1,803,072)

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Convertible notes discounts		$ 8,322

Accounts Receivable (Details Na

Accounts Receivable (Details Narrative) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Receivables [Abstract]
Accounts receivable	$ 130,259	$ 242,145
Allowance for uncollectible accounts	$ 216,302	$ 128,944

Other Current Assets - Schedule

Other Current Assets - Schedule of Other Current Assets (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Other Current Assets
Prepaid expenses	$ 39,901	$ 48,151
Other receivable	5,321	5,522
Total other current assets	$ 45,222	$ 53,673

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 83,265	$ 70,874

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Software	$ 124,697	$ 124,697
Office equipment	74,777	74,777
Furniture and fixtures	29,879	29,879
Lab equipment	1,398,716	1,398,716
Leasehold improvements	494,117	494,117
Lab equipment held under capital leases	99,193	99,193
Fixed assets, gross	2,221,379	2,221,379
Less: accumulated depreciation	(1,419,239)	(1,335,974)
Total	$ 802,140	$ 885,405

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Details) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease cost	$ 29,718
Amortization of assets	6,946
Interest on lease liabilities	2,330	$ 3,306
Total lease cost	$ 38,994

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Balance Sheet Information (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Leases [Abstract]
Operating lease assets	$ 483,200	$ 505,706
Current portion of operating lease liabilities	86,889	84,731
Noncurrent operating lease liabilities	401,170	423,752
Total operating lease liabilities	488,059
Equipment, at cost	99,193
Accumulated amortization	(24,798)
Equipment, net	74,395
Current portion of finance lease liability	34,053	32,532
Noncurrent finance lease liability	11,912	$ 20,379
Total finance lease liability	$ 45,965
Operating leases	4 years 8 months 2 days
Finance leases	1 year 3 months 19 days
Operating leases	5.75%
Finance lease	18.41%

Leases - Schedule of Suppleme_2

Leases - Schedule of Supplemental Cash Flow and Other Information (Details) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating cash flows used for operating leases	$ 20,424
Financing cash flows used for finance leases	6,946	$ 25,843
Total operating lease liabilities	528,616
Total finance lease liabilities	$ 99,193

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Annual Lease Commitments Under Operating Leases (Details)	Sep. 30, 2020USD ($)
Leases [Abstract]
2021	$ 84,147	[1]
2022	115,550
2023	119,468
2024	123,543
2025	116,891
Operating leases	$ 559,599
[1]	Liability pertains to the remaining nine month period from January 1, 2021 through September 30, 2021.

Leases - Schedule of Future M_2

Leases - Schedule of Future Minimum Annual Lease Payments Under Finance Lease (Details) - USD ($)		Dec. 31, 2020	Sep. 30, 2020
Leases [Abstract]
2021	[1]	$ 30,921
2022		21,644
Total minimum lease payments		52,565
Less interest		6,600
Present value of lease liabilities		45,965
Less current portion		34,053	$ 32,532
Long-term lease liabilities		$ 11,912	$ 20,379
[1]	Liability pertains to the remaining nine month period from January 1, 2021 through September 30, 2021.

Short Term Advances (Details Na

Short Term Advances (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Interest rates on short term loans	$ 1,023

Short Term Advances - Schedule

Short Term Advances - Schedule of Short Term Advances (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Total short term advances	$ 50,112	$ 50,112
Convertible Noteholders [Member]
Total short term advances	30,112	30,112
Convertible Noteholders One [Member]
Total short term advances	20,000	20,000
Convertible Noteholders Two [Member]
Total short term advances

Short Term Advances - Schedul_2

Short Term Advances - Schedule of Short Term Advances (Details) (Parenthetical) - USD ($)	Jul. 20, 2020	Jan. 21, 2020	Dec. 26, 2019
Convertible Notes holder [Member]
Proceeds from short-term loan	$ 30,112
Short term loan rate of interest	8.00%
Convertible Noteholder One [Member]
Proceeds from short-term loan		$ 20,000
Interest expense
Convertible Noteholders Two [Member]
Proceeds from short-term loan			$ 25,000
Debt maturity date			Feb. 6, 2020

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Interest expense	$ 26,567	$ 14,115
Note Payable [Member]
Interest expense	$ 4,131	$ 3,819

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Total notes payable	$ 459,935	$ 473,224
Less: current maturities	(55,102)	(54,317)
Note payable	404,833	418,907
Company PPP Note [Member]
Total notes payable	40,114	40,114
Labs PPP Note [Member]
Total notes payable	179,920	179,920
Bank Loan [Member]
Total notes payable	$ 239,901	$ 253,190

Notes Payable - Schedule of N_2

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) - USD ($)	Jun. 22, 2020	May 13, 2020	Dec. 26, 2019	Dec. 31, 2020	Dec. 31, 2019
Proceeds from bank loan					$ 25,000
Note Payable [Member]
Debt instrument interest percentage			5.75%
Debt instrument maturity date			Dec. 26, 2024
Payments for lab equipment			$ 377,124
Proceeds from bank loan			291,931
Debt instrument periodic payment			$ 5,622
Debt instrument term			5 years
Cross River Bank [Member] | Company PPP Note [Member]
Proceeds from notes payable	$ 40,114
Debt instrument interest percentage	1.00%
Debt instrument maturity date	Jun. 22, 2025
WebBankCorpMember | Labs PPP Note [Member] | Digipath Labs, Inc [Member]
Proceeds from notes payable		$ 179,920
Debt instrument interest percentage		1.00%
Debt instrument maturity date		May 13, 2022
Debt instrument description		Under the Payroll Protection Program, Labs will be eligible for loan forgiveness up to the full amount of the Labs PPP Note and any accrued interest. The forgiveness amount will be equal to the amount that Labs spends during the 8-week period beginning May 13, 2020 on payroll costs, payment of rent on any leases in force prior to February 15, 2020 and payment on any utility for which service began before February 15, 2020. The maximum amount of loan forgiveness for non-payroll expenses is 25% of the amount of the Labs PPP Note. No assurance is provided that Labs will obtain forgiveness under the Labs PPP Note in whole or in part.
Percentage of loan forgiveness for non-payroll expenses		25.00%

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020
Convertible notes discounts			$ 8,322
Debt discount amount	0	$ 8,322	$ 8,322
Convertible notes interest expense	26,567	$ 14,115
Convertible Notes Payable [Member]
Convertible notes discounts	$ 70,964
Maximum Share Amount [Member]
Maximum amount owned percentage of issued and outstanding common shares	4.99%

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Total convertible notes payable	$ 1,200,000	$ 1,250,000
Less: unamortized debt discounts		(8,322)
Total convertible debt	1,200,000	1,241,678
Less: current maturities
Convertible notes payable	1,200,000	1,241,678
Convertible Notes Payable One [Member]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Total convertible notes payable	150,000	150,000
Convertible Notes Payable Three [Member]
Total convertible notes payable	300,000	350,000
Convertible Notes Payable Four [Member]
Total convertible notes payable	200,000	200,000
Convertible Notes Payable Five [Member]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Six [Member]
Total convertible notes payable	$ 150,000	$ 150,000

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Dec. 29, 2020	Dec. 28, 2020	Sep. 30, 2020	Feb. 11, 2020	Feb. 10, 2020	Sep. 23, 2019	Nov. 08, 2018	Nov. 05, 2018	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2019
Proceeds from convertible note									$ 60,000
Secured Convertible Promissory Note [Member] | Accredited Investors [Member]
Debt principal amount	$ 10,000	$ 60,000		$ 50,000
Debt instrument interest percentage				9.00%
Debt maturity date				Aug. 11, 2022
Conversion price per share	$ 0.03	$ 0.03		$ 0.15
Proceeds from convertible note		$ 10,000
Shares of common stock converted	333,334
Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]
Debt principal amount	$ 50,000	$ 200,000		$ 150,000
Debt instrument interest percentage				9.00%
Debt maturity date				Aug. 11, 2022
Conversion price per share	$ 0.03	$ 0.03		$ 0.15
Proceeds from convertible note		$ 50,000
Shares of common stock converted	166,666
9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]
Debt principal amount	$ 50,000	$ 400,000			$ 350,000
Debt instrument interest percentage					9.00%
Debt maturity date					Aug. 10, 2022
Conversion price per share	$ 0.03	$ 0.03			$ 0.15
Proceeds from convertible note		$ 50,000
Shares of common stock converted	1,666,667
Senior Secured Convertible Note [Member]
Debt principal amount						$ 200,000
Debt instrument interest percentage						8.00%
Debt maturity date			Aug. 10, 2022			Aug. 10, 2022
Conversion price per share			$ 0.03			$ 0.11
Extended debt instrument maturity date			On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share.
Senior Secured Convertible Note One [Member]
Debt principal amount							$ 350,000
Debt instrument interest percentage							8.00%
Debt maturity date			Aug. 10, 2022				Aug. 10, 2022
Conversion price per share			$ 0.03				$ 0.14
Interest paid											$ 4,066
Extended debt instrument maturity date			The maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share.
Senior Secured Convertible Note Two [Member]
Debt principal amount								$ 150,000
Debt instrument interest percentage								8.00%
Debt maturity date			Aug. 10, 2022					Aug. 10, 2022
Conversion price per share			$ 0.03					$ 0.14
Extended debt instrument maturity date			The maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share.

Convertible Notes Payable - S_3

Convertible Notes Payable - Schedule of Interest Expense (Details) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Interest on short term loans	$ 1,023
Interest on capital leases	2,330	3,306
Interest on notes payable	4,131	3,819
Amortization of beneficial conversion features	8,322	8,321
Interest on convertible notes	26,567	14,115
Total interest expense	$ 42,373	$ 29,561

Changes in Stockholders' Equi_2

Changes in Stockholders' Equity (Details Narrative) - USD ($)	Dec. 30, 2020	Dec. 29, 2020	Dec. 28, 2020	Dec. 25, 2020	Dec. 31, 2020	Dec. 31, 2019	Feb. 12, 2021	Sep. 30, 2020
Class of Stock [Line Items]
Preferred stock, shares authorized					10,000,000			10,000,000
Preferred stock, par value					$ 0.001			$ 0.001
Preferred stock, shares designated remaining					4,000,000
Preferred stock, shares issued					1,325,942			1,325,942
Preferred stock, shares outstanding					1,325,942			1,325,942
Common stock par value					$ 0.001			$ 0.001
Common stock authorized					250,000,000			250,000,000
Common stock, shares issued					64,065,390			58,270,567
Common stock, shares outstanding					64,065,390			58,270,567
Common stock issued for services, value					$ 27,000	$ 24,750
Stock-based compensation expense					$ 17,060
9% Secured Convertible Notes [Member]
Class of Stock [Line Items]
Debt instrument interest percentage		9.00%
Debt instrument face amount		$ 110,000
Number of converted shares		3,666,668
Conversion price per share		$ 0.03
Consultant [Member] | Consulting Agreement [Member]
Class of Stock [Line Items]
Common stock issued for services			500,000
Common stock issued for services, value			$ 12,000
Chief Financial Officer [Member]
Class of Stock [Line Items]
Common stock issued for services				728,155
Common stock issued for services, value				$ 15,000
Common Stock [Member]
Class of Stock [Line Items]
Number of converted shares					3,666,668
Common stock issued for services					1,228,155	171,233
Common stock issued for services, value					$ 1,228	$ 172
Common Stock [Member] | Chairman [Member]
Class of Stock [Line Items]
Number of shares sold, during period	900,000
Proceeds from sale of stock	$ 20,250
Subsequent Event [Member]
Class of Stock [Line Items]
Common stock par value							$ 0.001
Common stock authorized							250,000,000
Common stock, shares issued							64,065,390
Common stock, shares outstanding							64,065,390
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					6,000,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued					1,325,942
Preferred stock, shares outstanding					1,325,942
Preferred stock convertible into common stock shares					6,629,710
Percentage of equity beneficial ownership					4.99%

Common Stock Options (Details N

Common Stock Options (Details Narrative) - $ / shares	Jun. 21, 2016	Dec. 31, 2020
Number of options outstanding		2,820,000
Number of options granted to purchase shares of common stock		750,000
Options exercise price per share		$ 0.10
2012 Stock Incentive Plan [Member] | Maximum [Member]
Number of shares issued under stock plan	11,500,000
Options exercisable period	10 years

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative)	Dec. 31, 2020$ / sharesshares
Number of warrant to purchase of common stock shares	3,877,024
Warrants [Member]
Number of warrant to purchase of common stock shares	397,245
Warrants exercise price per share | $ / shares	$ 0.26

Other Income (Expense) - Schedu

Other Income (Expense) - Schedule of Other Income (Expense) (Details) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Other Income and Expenses [Abstract]
Rental income on subleases		$ 21,000
Interest expense	(42,373)	(29,561)
Total other income (expense)	$ (42,373)	$ (8,561)

Income Tax (Details Narrative)

Income Tax (Details Narrative)	3 Months Ended
	Dec. 31, 2020USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 13,056,000
Operating loss expiration year	2031

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Jan. 12, 2021USD ($)
Subsequent Event [Member] | Company PPP Note [Member]
Forgiven note payable	$ 40,114